Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garrett M Draper

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Genes, Chromosomes & Cancer|March 24, 2023
Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line modelsGarrett M Draper, Daniel J Panken, David A Largaespada
The CRISPR Journal|August 16, 2022
Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing TechnologiesKelsie L Becklin, Garrett M Draper, Rebecca A Madden, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumorsKyle B Williams, Alex T Larsson, Bryant J Keller, et al.
Molecular Cancer Therapeutics|October 2, 2025
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumorsKyle B Williams, Alex T Larsson, Bryant J Keller, et al.
Nature Communications|November 21, 2019
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Oncogene|October 5, 2019
SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasisBranden A Smeester, Nicholas J Slipek, Emily J Pomeroy, et al.
Nature Communications|December 8, 2019
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Molecular Cancer Therapeutics|October 1, 2020
Implication of <i>ZNF217</i> in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic OsteosarcomaBranden A Smeester, Garrett M Draper, Nicholas J Slipek, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Genes, Chromosomes & Cancer|March 24, 2023
Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line modelsGarrett M Draper, Daniel J Panken, David A Largaespada
The CRISPR Journal|August 16, 2022
Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing TechnologiesKelsie L Becklin, Garrett M Draper, Rebecca A Madden, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumorsKyle B Williams, Alex T Larsson, Bryant J Keller, et al.
Molecular Cancer Therapeutics|October 2, 2025
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumorsKyle B Williams, Alex T Larsson, Bryant J Keller, et al.
Nature Communications|November 21, 2019
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Oncogene|October 5, 2019
SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasisBranden A Smeester, Nicholas J Slipek, Emily J Pomeroy, et al.
Nature Communications|December 8, 2019
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Molecular Cancer Therapeutics|October 1, 2020
Implication of <i>ZNF217</i> in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic OsteosarcomaBranden A Smeester, Garrett M Draper, Nicholas J Slipek, et al.
Pageof 1